XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 28,155 $ 32,154
Marketable securities 32,940 37,072
Prepaid and other current assets 4,203 2,650
Total current assets 65,298 71,876
Property and equipment, net 262 296
Finite-Lived Intangible Assets, Net 317 334
Other assets 449 528
Total assets 66,326 73,034
Liabilities    
Accounts payable 1,341 2,655
Accrued liabilities 3,945 3,728
Total current liabilities 5,286 6,383
Other long-term liabilities 337 327
Total liabilities 5,623 6,710
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,999,080 and 7,866,799 shares at March 31, 2023 and December 31, 2022, respectively; and outstanding, 7,998,342 and 7,866,061 shares at March 31, 2023 and December 31, 2022, respectively 8 8
Additional paid-in capital 575,137 574,548
Treasury stock, at cost; 738 shares at March 31, 2023 and December 31, 2022 (708) (708)
Accumulated deficit (513,428) (507,241)
Accumulated other comprehensive loss (52) (29)
Total Lisata Therapeutics, Inc. stockholders' equity 60,957 66,578
Non-controlling interests (254) (254)
Total stockholders' equity 60,703 66,324
Total liabilities, non-controlling interests and stockholders' equity $ 66,326 $ 73,034